Wockhardt has advanced its anti-infective portfolio with ZAYNICH, a first-in-class antibiotic developed for adults with complicated urinary tract infections and associated Gram-negative bloodstream infections.
The therapy is supported by positive clinical study outcomes and strengthens the company's focus on tackling antimicrobial resistance.
The company's ENHANCE-1 Phase 3 trial evaluated ZAYNICH against meropenem in patients with complicated urinary tract infections, including pyelonephritis. The study measured both clinical cure and microbiological eradication.
ZAYNICH achieved the primary endpoint in 89% of patients, with 250 out of 281 participants responding successfully. Meropenem recorded a success rate of 68.4%, with 93 out of 136 patients meeting the same endpoint. The difference of 20.6% points favoured ZAYNICH.
The results were assessed around 10 days after completion of treatment. Among patients who also had Gram-negative bacteremia at baseline, ZAYNICH delivered an 89% response rate compared with 44% for meropenem.
Before entering Phase 3, the antibiotic completed nine Phase 1 studies and a Phase 2 study conducted across 15 leading tertiary-care hospitals in India.
The Phase 2 study focused on meropenem-resistant Gram-negative infections and reported clinical efficacy of more than 97%. The trial included patients with hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, bloodstream infections, complicated intra-abdominal infections and complicated urinary tract infections.
The company believes the treatment can address carbapenem-resistant and extensively drug-resistant Gram-negative infections, areas where existing therapies can face efficacy and safety challenges.
ZAYNICH has also been designed to tackle metallo-β-lactamase-mediated resistance, a significant resistance mechanism seen in India.
ZAYNICH combines Zidebactam and Cefepime in an injectable formulation. The 2 compounds target different penicillin-binding proteins, helping eliminate Gram-negative bacteria through a dual-action approach.
The therapy has also demonstrated encouraging outcomes in 85 compassionate-use cases involving extensively drug-resistant Gram-negative infections across India, the United States, Malaysia and France.
Wockhardt currently has 6 antibiotics in its pipeline, split equally between Gram-negative and Gram-positive infection treatments. The company employs around 3,200 people across global operations, with international markets contributing 78% of overall revenue.
As of 29 May 2026, at 11:11 AM, Wockhardt Ltd share price is trading at ₹1,917.60 per share, reflecting a surge of 8.19% from the previous closing price.
ZAYNICH adds a significant product to Wockhardt's anti-infective portfolio, supported by strong clinical evidence across multiple studies and a focus on treating difficult drug-resistant bacterial infections.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 29, 2026, 11:35 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
